INNOGEN-B (02591) rose more than 3% during morning trading. At the time of writing, the stock was up 2.94% to HK$22.22, with a turnover of HK$1.966 million. On April 1, INNOGEN announced via its official social media account that Esupaglutide Alpha (Yinuoqing®) has been officially included in the specific drug list for online outpatient services under the "Qilu Insurance" program, for the treatment of adult patients with type 2 diabetes. Clinical studies have shown that Esupaglutide Alpha, as a new-generation GLP-1 drug, demonstrates effective glucose-lowering results in the treatment of type 2 diabetes in adults. Additionally, positive data has been observed in weight-loss related clinical studies conducted in China and Australia. As a supplement to the flexible use of drugs listed in the National Reimbursement Drug List, this initiative represents the first and currently only practice in China combining a Class 1 GLP-1 innovative drug with commercial insurance online outpatient services. This move marks a significant step for INNOGEN in enhancing the accessibility of its innovative drug Yinuoqing® and supporting chronic disease management.